SG Americas Securities LLC Makes New $1.32 Million Investment in uniQure N.V. $QURE

SG Americas Securities LLC bought a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 94,759 shares of the biotechnology company’s stock, valued at approximately $1,321,000. SG Americas Securities LLC owned approximately 0.17% of uniQure at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in QURE. Aberdeen Group plc lifted its position in uniQure by 24.2% in the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after buying an additional 535,163 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of uniQure in the second quarter worth $1,952,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of uniQure during the second quarter worth $872,000. Cubist Systematic Strategies LLC acquired a new stake in uniQure during the first quarter valued at $2,562,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in uniQure in the first quarter valued at about $152,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 314,560 shares of company stock worth $12,362,568 in the last 90 days. Insiders own 4.79% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on QURE shares. The Goldman Sachs Group cut their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald raised their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. William Blair reiterated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Mizuho increased their price target on shares of uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. Finally, Stifel Nicolaus raised their price target on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.42.

uniQure Stock Down 0.3%

Shares of uniQure stock opened at $27.81 on Friday. uniQure N.V. has a 12-month low of $5.70 and a 12-month high of $71.50. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a 50 day moving average price of $44.45 and a two-hundred day moving average price of $25.17. The stock has a market capitalization of $1.73 billion, a P/E ratio of -7.09 and a beta of 0.59.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Equities analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.